Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Mediwound Ltd (MDWD)

NASDAQ
Currency in USD
16.970
-1.100(-6.09%)
Closed
After Hours
16.9700.000(0.00%)
MDWD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
16.89317.940
52 wk Range
9.87624.000
Key Statistics
Edit
Prev. Close
18.07
Open
17.94
Day's Range
16.893-17.94
52 wk Range
9.876-24
Volume
44.4K
Average Volume (3m)
43.7K
1-Year Change
73.87%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDWD Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
29.000
Upside
+70.890%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period
Show more

Mediwound Ltd Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Employees
0

Mediwound Ltd Earnings Call Summary for Q4/2024

  • NexoBrid received FDA approval for pediatric use; Q3 revenue $4.4M, down from $4.8M in Q3 2023; 9-month revenue up to $14.4M
  • EscharEx Phase 3 trials for venous leg ulcers in preparation; $25M raised through private investment; $46M cash and equivalents reported
  • New NexoBrid manufacturing facility to be operational by end of 2025; temperature-stable formulation in development
  • 2024 NexoBrid revenue forecast adjusted from $24M to $20M; current product shortage limiting European stockpile supply
  • Over 70 burn centers submitted for NexoBrid, ~50 approved; WHO recognized enzymatic debridement as essential for burn injuries
Last Updated: 2024/11/26, 16:22
Read Full Transcript

Compare MDWD to Peers and Sector

Metrics to compare
MDWD
Peers
Sector
Relationship
P/E Ratio
−6.5x−5.9x−0.7x
PEG Ratio
0.070.000.00
Price/Book
5.3x2.8x2.6x
Price / LTM Sales
9.3x1.7x3.2x
Upside (Analyst Target)
62.1%97.5%46.6%
Fair Value Upside
Unlock6.3%7.4%Unlock

Analysts' Recommendations

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.000

(+70.89% Upside)

FAQ

What Is the Mediwound (MDWD) Stock Price Today?

The Mediwound stock price today is 16.97

What Stock Exchange Does Mediwound Trade On?

Mediwound is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Mediwound?

The stock symbol for Mediwound is "MDWD."

What Is the Mediwound Market Cap?

As of today, Mediwound market cap is 183.11M.

What is Mediwound Earnings Per Share?

The Mediwound EPS is -2.93.

What Is the Next Mediwound Earnings Date?

Mediwound will release its next earnings report on 12 Mar 2025.

From a Technical Analysis Perspective, Is MDWD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.